A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •1. Has known hypersensitivity to any oligodeoxynucleotide
• •2. Is nursing
• •3. Has body weight \<50 kg
• •4. Has BMI \>34.9 kg/m2
• •5. Regularly consumes \>3 drinks of alcoholic beverages (beer, wine, or distilled spirits) per day
• •6. Has a positive test for antibody to human immunodeficiency virus (HIV-1 or -2) or hepatitis C virus (HCV)
• •7. Has a positive test for hepatitis B surface antigen (HBsAg)
• •8. Has at screening safety laboratory tests meeting one or more of the following criteria:
• •* hemoglobin \<6.52 mmol/L (\<10.5 g/dL)
• •* white blood cell count \<4x109/L ( \<4,000/mm3)
• •* absolute neutrophil count (ANC) \<1.5x109/L (\<1500/mm3)
• •* platelet count \<100x109/L (\<100,000/mm3 )
• •* serum creatinine \>1.3x ULN;
• •* alanine transaminase (ALT; SGPT) \>2.5x ULN
• •* aspartate transaminase (AST; SGOT) \>2.5x ULN
• •* serum total bilirubin \>1.4x ULN (except if consistent with Gilbert's disease: i.e., total bilirubin \<103 μmol/L (6 mg/dL) and conjugated bilirubin \<1.2x ULN)
• •9. Has a history of allogeneic organ transplant (including bone marrow or stem cells)
• •10. Has, within the past 10 years, had evidence of or required treatment for cancer (except for treated, non-invasive carcinoma of the skin or cured cervical carcinoma-in-situ)
• •11. Has had within the past three months or is expected to have during the study period any of the following treatments:
• •* surgery requiring general anesthesia
• •* hematopoietic stimulating agents (e.g., erythropoietin, G-CSF, GM-CSF)
• •* another investigational drug;
• •12. Has other significant medical conditions (chronic or active within the past 6 months), including, but not limited to: cardiac disease (e.g., unstable angina, myocardial infarction, congestive heart failure, ventricular arrhythmia); uncontrolled seizure disorder; liver disease; uncontrolled diabetes
• •13. Has any other condition that would, in the opinion of the Investigator, potentially compromise the safety or compliance of the patient or may preclude the patient's successful completion of the clinical trial